Using Population-Based Cancer Registration Data and Period Analysis to Accurately Assess and Predict 5-Year Relative Survival for Lung Cancer Patients in Eastern China

Li, Runhua; Zhang, Min; Cheng, Yongran; Jiang, Xiyi; Tang, Huijuan; Wang, Liangyou; Chen, Tianhui; Chen, Bicheng

doi:10.3389/fonc.2021.661012

Cited by 6 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, those who went to the hospital were more likely to have a stronger willingness to treatment and capacity to pay, and thus to receive better medical consultation and rehabilitation guidance, which emphasized the significance of active treatment. In addition, some studies reported higher survival in other regions (15,35,36), and the leading reason might be the decreases in the proportions of advanced lung cancer (stage III and stage IV).…”

Section: Discussionmentioning

confidence: 99%

“…Up to now, there have been several reports on the survival of lung cancer patients in Chinese population (12)(13)(14)(15)(16)(17) but they were mostly single-center studies with poor representativeness. A survival analysis based on 17 cancer registries in China with long-term follow-up (6) assessed the 5-year survival rates and the trends for all cancer types in recent years, but it lacked the specific survival in pathological stages and histological classifications.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Survival of 7,311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in China

He¹,

Li²,

Cao³

et al. 2022

Transl Lung Cancer Res

Self Cite

View full text Add to dashboard Cite

Background: Representative prognostic data by clinical characteristics for lung cancer is not yet available in China. This study aimed to calculate the survival of lung cancer patients with different pathological evaluations, explore their predictive effects and provide information for prognosis improvement. Methods:In this multicenter cohort study, primary lung cancer patients diagnosed in 17 hospitals at three distinct levels in China between 2011-2013 were enrolled and followed up till 2020. Overall survival and lung cancer specific survival were calculated by Kaplan-Meier method. Cox proportional hazards model was applied to assess the effects of predictors of lung cancer survival.Results: Of all the 7,311 patients, the 5-year overall and lung cancer specific survival rates were 37.0% and 41.6%, respectively. For lung cancer patients at stages I, II, III, and IV, the 5-year overall survival rates were 76.9%, 56.1%, 32.6%, and 21.4%, respectively; the lung cancer specific survival rates were 82.3%, 59.7%, 37.2%, and 26.4%, respectively. Differences of survival for each stage remained significant between histological classifications (P<0.01). The 5-year overall survival rates for patients with squamous cell carcinoma, adenocarcinoma (AC), and small cell carcinoma were 36.9%, 43.3% and 27.9%, respectively; the corresponding disease-specific rates were 41.5%, 48.6% and 31.0%, respectively. Such differences were nonstatistically significant at advanced stages (P=0.09). After multivariate adjustments, stage and classification remained independent predictors for the survival of lung cancer. Conclusions:The prognosis of lung cancer varied with the pathological stages and histological classifications, and had room for improvement. Stage was the strongest predictor, so efforts on early detection and treatment are needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Survival of 7,311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in China

He¹,

Li²,

Cao³

et al. 2022

Transl Lung Cancer Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…The mortality rate of lung cancer was about 75% in the United States at the beginning of the 20th century [ 28 ]. Although it is estimated that the 5-year survival rate of NSCLC was increased from 40.2% in 2014–2018 to 52.7% in 2019–2023 in China [ 29 , 30 ], it is often diagnosed in advanced stages with a poor prognosis. Thus, there is an urgent need to elucidate the mechanism of lung cancer to identify potential therapeutic targets or prognostic biomarkers.…”

Section: Discussionmentioning

confidence: 99%

miRNAs-mediated overexpression of Periostin is correlated with poor prognosis and immune infiltration in lung squamous cell carcinoma

Chen

Oliver

2022

Aging

View full text Add to dashboard Cite

Lung cancer is one of the most common malignancies with a high mortality rate worldwide. POSTN has been shown to be strongly correlated with the poor prognosis of lung cancer patients. However, the function and mechanism of action of POSTN in lung cancer remain unclear. Here, we carried out a pan-cancer analysis to assess the clinical prognostic value of POSTN based on the TCGA, TIMER, Oncomine, Kaplan-Meier, and UALCAN databases. We found that upregulated POSTN can be a promising biomarker to predict the prognosis of patients with lung cancer. High levels of POSTN correlated with immune cell infiltration in lung cancer, especially lung squamous cell carcinoma (LUSC), which was further confirmed based on the results from the TISIDB database. Moreover, the expression analysis, correlation analysis, and survival analysis revealed that POSTN-targeted miRNAs, downregulation of has-miR-144-3p and has-miR-30e-3p, were significantly linked to poor prognosis in patients with LUSC. Taken together, we identified that POSTN can act as a novel biomarker for determining the prognosis related to immune infiltration in patients with LUSC and deserves further research.

show abstract

“…Other investigations also suggested of improved survival for breast cancer patients due to early detection, early diagnosis and early treatment, as well as better socioeconomic status and diet ( 39 ) ( 40 ). Besides, Taizhou City is located in East China, with a relatively constantly prosperous economy, universal medical insurance system, and continuously improving health awareness, which may continue to contribute to future improvements of breast cancer survival in Taizhou City ( 7 , 10 ).…”

Section: Discussionmentioning

confidence: 99%

“…There is a global technical problem in assessing the long-term relative survival of cancer patients in a timely and accurate manner ( 8 ). The period analysis, first introduced in 1996 by Brenner and Gefeller ( 8 ), is the gold standard for the assessment of long-term survival of cancer patients from population-based cancer registry data and has been widely used globally ( 7 , 9 , 10 ). In addition, Brenner and his colleagues also proposed the model-based period analysis in 2006, which could provide a more precise survival prediction for the subsequent survival for cancer patients ( 11 ).…”

Section: Introductionmentioning

confidence: 99%

Use of period analysis to timely assess 5-year relative survival for breast cancer patients from Taizhou, Eastern China

Zheng

Huang

et al. 2022

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

ObjectivesWhile timely assessment of long-term survival for patients with breast cancer is essential for evaluation on early detection and screening programs, those data are extremely scant in China. We aimed to derive most up-to-date survival estimates and to predict future survival using the cancer registry data from Taizhou city, Eastern China.MethodsPatients diagnosed with breast cancer during 2004-2018 from four cancer registries with high-quality data from Taizhou, Eastern China were included. Period analysis was used to calculate 5-year relative survival (RS) for the overall population and according to the stratification factors sex, age at diagnosis and geographic region. We further predict the upcoming 5-year RS during 2019-2023, using continuous data from three 5-year periods (2004-2008, 2009-2013 and 2014-2018) and a model-based period approach.ResultsOverall 6159 patients diagnosed with breast cancer during 2004-2018 were enrolled. The 5-year RS for breast cancer in 2014-2018 reached 88.8%, while women were higher compared to men (90.5% versus 83.7%) and urban areas were higher compared to rural areas (91.9% versus 86.7%). Additionally, we found a clear gradient by age at diagnosis, ranging from 94.8% for age<45 years to 83.3% for age>74 years. Projected overall 5-year RS for the upcoming 2019-2023 could reach 91.5% (84.8% for men and 93.5% for women).ConclusionsWe provided, for first time in China, using period analysis, most up-to-date 5-year RS (88.8%) for patients with breast cancer from Taizhou, Eastern China. We also demonstrate the 5-year RS has improved greatly over last 15 years, which has important implications for timely evaluation of early detection and screening programs.

show abstract

Using Population-Based Cancer Registration Data and Period Analysis to Accurately Assess and Predict 5-Year Relative Survival for Lung Cancer Patients in Eastern China

Cited by 6 publications

References 33 publications

Survival of 7,311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in China

Survival of 7,311 lung cancer patients by pathological stage and histological classification: a multicenter hospital-based study in China

miRNAs-mediated overexpression of Periostin is correlated with poor prognosis and immune infiltration in lung squamous cell carcinoma

Use of period analysis to timely assess 5-year relative survival for breast cancer patients from Taizhou, Eastern China

Contact Info

Product

Resources

About